8-K: NeuroBo Pharmaceuticals Announces Poster Presentations for Cardiometabolic Assets at Major Scientific Conferences

NeuroBo Pharmaceuticals will present pre-clinical data on its drug candidates DA-1241 and DA-1726 at the EASL Congress 2024 and the American Diabetes Association 84th Scientific Sessions in June.

Summary

• NeuroBo Pharmaceuticals has announced the acceptance of poster presentations for its cardiometabolic assets, DA-1241 and DA-1726, at two major scientific conferences in June.
• DA-1241, a GPR119 agonist, is being developed for the treatment of MASH and Type 2 Diabetes, and has shown positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism in preclinical studies.
• DA-1726, a dual GLP1R/GCGR agonist, is being developed for the treatment of obesity and has demonstrated sustained weight loss in preclinical models by decreasing food consumption and boosting energy expenditure.
• The company has completed enrollment for Part 1 of the Phase 2a clinical trial of DA-1241 and has dosed the first patient in the single ascending dose (SAD) Part 1 of the Phase 1 trial of DA-1726.
• Top-line data from the SAD Part 1 of the DA-1726 trial is expected in the third quarter of 2024, with top-line data from the multiple ascending dose (MAD) Part 2 expected in the first quarter of 2025.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment due to the acceptance of poster presentations at major conferences and the progress of clinical trials. However, it also includes standard risk disclosures, which temper the overall optimism.

Positives

• The acceptance of multiple poster presentations at prestigious scientific conferences highlights the scientific community's recognition of NeuroBo's pre-clinical data.
• The company has completed enrollment for Part 1 of the Phase 2a clinical trial of DA-1241.
• The company has dosed the first patient in the single ascending dose (SAD) Part 1 of the Phase 1 trial of DA-1726.
• The clinical timelines for DA-1726 have been significantly accelerated.
• Preclinical data for DA-1241 shows positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism.
• Preclinical data for DA-1726 shows sustained weight loss by decreasing food consumption and boosting energy expenditure.

Risks

• The company's ability to execute its commercial strategy and obtain regulatory approvals for its drug candidates is subject to risks and uncertainties.
• There are risks associated with the cooperation of contract manufacturers, clinical study partners, and others involved in the development of NeuroBo's product candidates.
• Potential negative interactions between NeuroBo's product candidates and other products used in treatment could impact results.
• The company's ability to initiate and complete clinical trials on a timely basis and recruit subjects is subject to risks.
• Clinical trial results may not be consistent with pre-clinical and previous clinical trial results.
• Changes in applicable laws or regulations could impact the company.
• Changes to NeuroBo's stock price could affect the terms of the license agreement and any future fundraising.

Future Outlook

The company expects to dose the first patient in the multiple ascending dose (MAD) Part 2 of the DA-1726 trial and read-out top-line data from the SAD Part 1 in the third quarter of 2024, with top-line data from the MAD Part 2 expected in the first quarter of 2025.

Management Comments

• Hyung Heon Kim, President and Chief Executive Officer of NeuroBo, stated that the multiple poster selections at two esteemed scientific forums emphasize the scientific community's recognition of the compelling pre-clinical data for DA-1241 and DA-1726.
• Hyung Heon Kim also noted that the clinical timelines for DA-1726 have been significantly accelerated.

Industry Context

This announcement is relevant to the broader pharmaceutical industry's focus on developing treatments for cardiometabolic diseases, including MASH and obesity. The presentation of pre-clinical data at major scientific conferences is a key step in the drug development process and can attract interest from potential partners and investors.

Comparison to Industry Standards

• The development of GPR119 agonists like DA-1241 for MASH is in line with industry trends, with companies like 89bio and Madrigal Pharmaceuticals also pursuing similar targets.
• The development of dual GLP1R/GCGR agonists like DA-1726 for obesity is a competitive area, with companies like Eli Lilly (Tirzepatide) and Novo Nordisk (Semaglutide) leading the market with their GLP-1 based therapies.
• The presentation of pre-clinical data at conferences like EASL and ADA is a standard practice for biotech companies to showcase their research and attract interest from the scientific community and potential investors.
• The timelines for clinical trials, with top-line data expected in the third quarter of 2024 and first quarter of 2025, are typical for early-stage clinical development.

Stakeholder Impact

• Shareholders may view the news positively due to the progress in clinical trials and the recognition of the company's research.
• Employees may be motivated by the progress of the company's drug development programs.
• The scientific community will be interested in the pre-clinical data presented at the conferences.
• Potential partners and investors may be attracted by the positive results and the company's progress.

Next Steps

• NeuroBo will present pre-clinical data on DA-1241 at the EASL Congress 2024 in June.
• NeuroBo will present pre-clinical data on DA-1726 at the American Diabetes Association 84th Scientific Sessions in June.
• The company expects to dose the first patient in the multiple ascending dose (MAD) Part 2 of the DA-1726 trial in the third quarter of 2024.
• The company expects to read-out top-line data from the SAD Part 1 of the DA-1726 trial in the third quarter of 2024.
• The company expects to read-out top-line data from the MAD Part 2 of the DA-1726 trial in the first quarter of 2025.

Key Dates

Keywords

Cardiometabolic, MASH, Obesity, DA-1241, DA-1726, GPR119 agonist, GLP1R/GCGR dual agonist, Clinical trials, Pre-clinical data, EASL Congress, American Diabetes Association